{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-087678","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.835322+00:00","generated_at":"2026-05-19T02:57:19.957183+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Fractyl Health gets two new U.S. patents for duodenal resurfacing, portfolio now 31 granted patents","bullets":["U.S. Patent No. 12,329,439 (June 17, 2025) and No. 12,303,185 (May 20, 2025) cover thermal and non-thermal electrical energy ablation of duodenal mucosa.","Total IP estate: 31 granted U.S. patents and ~40 pending applications, built since 2011.","Revita next milestones: REVEAL-1 open-label data June 2025, REMAIN-1 midpoint Q3 2025, primary endpoint H2 2026.","Patents reinforce Fractyl's leadership in gut-targeted metabolic therapies for obesity and type 2 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-087678","json":"https://secwatch.observer/filing/0000950170-25-087678.json","markdown":"https://secwatch.observer/filing/0000950170-25-087678.md","text":"https://secwatch.observer/filing/0000950170-25-087678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025087678/0000950170-25-087678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025087678/guts-20250618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T02:57:19.957183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}